Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Vacuolar-sorting Protein SNF8 (SNF8) Peptide

SNF8 Reactivity: Human Host: Synthetic BP, WB, IHC
Catalog No. ABIN976089
  • Target See all SNF8 products
    SNF8 (Vacuolar-sorting Protein SNF8 (SNF8))
    Origin
    Human
    Source
    • 5
    Synthetic
    Application
    Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
    Characteristics
    This is a synthetic peptide designed for use in combination with anti-SNF8 antibody (Catalog #: ARP31531_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
    Purification
    Purified
  • Application Notes
    Each Investigator should determine their own optimal working dilution for specific applications.
    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
    Concentration
    1 mg/mL
    Buffer
    Final peptide concentration is 1 mg/mL in PBS.
    Handling Advice
    Avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
  • Target
    SNF8 (Vacuolar-sorting Protein SNF8 (SNF8))
    Synonyms
    d11moh34 Peptide, vps22 Peptide, Dot3 Peptide, EAP30 Peptide, VPS22 Peptide, D11moh34 Peptide, RGD1310144 Peptide, D11Moh34 Peptide, D11MOH34 Peptide, zgc:101578 Peptide, SNF8, ESCRT-II complex subunit Peptide, eap30 subunit of ell complex, putative Peptide, EAP30 subunit of ELL complex Peptide, SNF8, ESCRT-II complex subunit S homeolog Peptide, SNF8, ESCRT-II complex subunit, homolog (S. cerevisiae) Peptide, snf8 Peptide, TA17290 Peptide, TVAG_107410 Peptide, Bm1_05145 Peptide, SNF8 Peptide, Snf8 Peptide, snf8.S Peptide
    Background
    ELL encodes an RNA polymerase II transcription factor that undergoes frequent translocation in acute myeloid leukemia (AML). In addition to its elongation activity, ELL contains a novel type of RNA polymerase II interaction domain that is capable of repressing polymerase activity in promoter-specific transcription. EAP30 is a subunit of the ELL complex. EAP30 can interact with ELL and derepress ELL's inhibitory activity in vitro.SNF8, VPS25 (MIM 610907), and VPS36 (MIM 610903) form ESCRT-II (endosomal sorting complex required for transport II), a complex involved in endocytosis of ubiquitinated membrane proteins. SNF8, VPS25, and VPS36 are also associated in a multiprotein complex with RNA polymerase II elongation factor (ELL, MIM 600284) (Slagsvold et al., 2005 [PubMed 15755741], Kamura et al., 2001 [PubMed 11278625]).[supplied by OMIM].

    Alias Symbols: Dot3, EAP30, VPS22

    Protein Interaction Partner: CHMP6,DVL2,ELL,NIF3L1,TSG101,VPS25,VPS36,DVL2,ELL,NIF3L1,VPS25

    Protein Size: 258
    Molecular Weight
    29 kDa
    Gene ID
    11267
    NCBI Accession
    NM_007241, NP_009172
    UniProt
    Q96H20
You are here:
Support